Yulong He，Professor

Academic History:

M.Sc., Nanjing Agricultural University, Reproductive Biology, China,1989-1992  

Ph.D., University of Cambridge, Molecular Biology, 1996-1999  

Post-Doc., University of Cambridge, Department of Pathology, UK,  1999-2000

Post-Doc., University of Helsinki, Molecular and Cancer Biology, Biomedicum Helsinki, Finland, 2000-2005

Professor,  Nanjing University, Model Animal Research Center, China, 2005-2011

Visiting Scientist, Korea Advanced Institute of Science and Technology, Korea, 2016-2016

Visiting Scientist, Max Planck Institute for Molecular Biomedicine, Germany, 2016-2017

Professor,  Soochow University, Cyrus Tang Hematology Center, China, 2011-present 

Research Interests:

1、Regulation of lymphatic and blood vascular network formation, remodeling, and valve development.

2、Mechanism of tumor lymphangiogenesis, angiogenesis and metastasis.

3、Molecular imaging of vasculature and tumor

Research Experience and Accomplishments:

Yulong He received his Ph.D. in Molecular Biology from University of Cambridge in 1999, and then did his Postdoctoral training in the Department of Pathology, University of Cambridge (Apr. 1999- Nov. 2000), and Molecular Cancer Biology Laboratory, University of Helsinki (Nov. 2000 – May 2005). From June 2005, he took the position of Professor /Principal Investigator in Model Animal Research Institute, Nanjing University. Since July 2011, he has been employed as a distinguished Professor by Soochow University, and as a visiting Scientist in Korea Advanced Institute of Science and Technology, Center for Vascular Research (Jan.- Feb. 2016) and Max Planck Institute for Molecular Biomedicine (May 2016-May 2017). Major goals of his research are to understand mechanisms underlying lymphatic and blood vascular formation as well as their functions in health and diseases. He published over 30 scientific papers with >2600 SCI citations (H-index 20).

Academic Awards and Honors:

2005, Ministry of Education of China (NCET: Program for New Century Excellent Talents in University)

2016, Outstanding Achievement Award (Science and Technology) Scientific and Technological Progress Award of Higher Education in 2015 (10/11).

Main Publications:

1、Jiang H#, Zhang L#, Liu X#, Sun W, Kato K, Chen C, Li X, Li T, Sun Z, Han W, Zhang F, Xiao Q, Yang Z, Hu J, Qin Z, Adams RH, Gao X, He Y*. Angiocrine FSTL1 (Follistatin-Like Protein 1) Insufficiency Leads to Atrial and Venous Wall Fibrosis via SMAD3 Activation. Arterioscler Thromb Vasc Biol 2020 40:958–972. doi: 10.1161/ATVBAHA.119.313901. bioRxiv 616623; doi: https://doi.org/10.1101/616623.

2、Hu X, Deng Q, Ma L, Li Q, Chen Y, Liao Y, Zhou F, Zhang C, Shao L, Feng J, He T, Ning W, Kong Y, Huo Y, He A, Liu B, Zhang J, Adams R, He Y, Tang F, Bian X, Luo J. Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res. 2020 30: 229–243. doi: 10.1038/s41422-020-0287-8. 3、He Y*. Angiopoietins and TIE Receptors in Lymphangiogenesis and Tumor Metastasis. In: Marmé D. (eds) Tumor Angiogenesis- A Key Target for Cancer Therapy. 2019 Springer, Cham. DOI: 10.1007/978-3-319-31215-6_43-1.

4、Zheng Y; Liu C; Li Y; Jiang H; Yang P; Tang J; Xu Y; Wang H; He Y*. Loss-of-function mutations with circadian rhythm regulator Per1/Per2 lead to premature ovarian insufficiency. Biol Reprod. 2019 100(4):1066-1072. doi:10.1093/biolre/ioy245.

5、Lee SJ, Lee CK, Kang S, Park I, Kim YH, Kim SK, Hong SP, Bae H, He Y, Kubota Y, Koh GY. Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction. J Clin Invest. 2018 Nov 1;128(11):5018-5033. doi: 10.1172/JCI99659. Epub 2018 Oct 8.

6、Li P, Wei G, Cao Y, Deng Q, Han X, Huang X, Huo Y, He Y, Chen L, Luo J. Myosin IIa is critical for cAMP-mediated endothelial secretion of von Willebrand factor. Blood 2018 131:686-698. doi: 10.1182/blood-2017-08-802140. Epub 2017 Dec 5

7、何玉龙*，朱元贵，李伯良，董尔丹*，淋巴管系统相关研究现状与展望，科学通报，2017，62（10）：1030-1040.

8、Kim J, Park DY, Bae H, Park DY, Kim D, Lee CK, Song S, Chung TY, Lim DH, Kubota Y, Hong YK, He Y, Augustin HG, Oliver G, Koh GY. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma. J Clin Invest. 2017 Oct 2;127(10):3877-3896. doi: 10.1172/JCI94668. Epub 2017 Sep 18.

9、Park DY, Lee J, Kim J, Kim K, Hong S, Han S, Kubota Y, Augustin HG, Ding L, Kim JW, Kim H, He Y, Adams RH, Koh GY. Plastic roles of pericytes in the blood-retinal barrier. Nat Commun. 2017 May 16;8:15296. doi: 10.1038/ncomms15296.

10、Chu M#, Li T#, Shen B, Cao X, Zhong H, Zhang L, Zhou F, Ma W, Jiang H, Xie P, Liu Z, Dong N, Xu Y, Zhao Y, Xu G, Lu P, Luo J, Wu Q, Alitalo K, Koh GY, Adams RH, He Y*. Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFII. Elife. 2016 Dec 22;5. pii: e21032. doi: 10.7554/eLife.21032.

11、Chen L, Li J, Wang F, Dai C, Wu F, Liu X, Li T, Glauben R, Zhang Y, Nie G, He Y*, Qin Z*. Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy. Cancer Res. 76(23):6828-6838 (2016).

12、Park JS, Kim IK, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo DC, He Y, Augustin HG, Kim I, Lee D, Koh GY. Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. Cancer Cell 30(6):953-967 (2016).

13、Han S, Lee SJ, Kim KE, Lee HS, Oh N, Park I, Ko E, Oh SJ, Lee YS, Kim D, Lee S, Lee DH, Lee KH, Chae SY, Lee JH, Kim SJ, Kim HC, Kim S, Kim SH, Kim C, Nakaoka Y, He Y, Augustin HG, Hu J, Song PH, Kim YI, Kim P, Kim I, Koh GY. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 8(335):335ra55 (2016). doi: 10.1126/scitranslmed.aad9260.

14、Shen B#, Shang Z#, Wang B#, Zhang L#, Zhou F#, Li T, Chu M, Jiang H, Wang Y, Qiao T, Zhang J, Sun W, Kong X, He Y*. Genetic dissection of TIE pathway in lymphatic maturation and valve development. Arterioscler Thromb Vasc Biol 34:1221-1230 (2014).

15、Zhang Y, Lu Y, Ma L, Cao X, Xiao J, Chen J, Jiao S, Gao Y, Liu C, Duan Z, Li D, He Y, Wei B, Wang H Activation of Vascular Endothelial Growth Factor Receptor-3 in Macrophages Restrains TLR4-NF-κB Signaling and Protects against Endotoxin Shock. Immunity. 40:501-514 (2014).

16、Xiong Y, Hu Z, Han X, Jiang B, Zhang R, Zhang X, Lu Y, Geng C, Li W, He Y, Huo Y, Shibuya M, Luo J. Hypertensive stretch regulates endothelial exocytosis of Weibel-Palade bodies through VEGF receptor 2 signaling pathways. Cell Res 23:820-34 (2013).

17、Li T, Yang J, Zhou Q, He Y*. Molecular Regulation of Lymphangiogenesis in Development and Tumor Microenvironment. Cancer Microenviron. 5:249-260 (2012).

18、Lu Y, Xiong Y, Huo Y, Han J, Yang X, Zhang R, Zhu DS, Klein-Heßling S, Li J, Zhang X, Han X, Li Y, Shen B, He Y, Shibuya M, Feng GS, Luo J. Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway. Proc Natl Acad Sci U S A. 108:2957-2962 (2011).

19、Zhang L^#, Zhou F^#, Han W^#, Shen B, Luo J, Shibuya M, He Y*. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res 20:1319-31 (2010)-Cover paper.

20、Zhou F^#, Chang Z^#, Zhang L^#, Hong Y, Shen B, Wang B, Zhang F, Lu F, Tvorogov D, Alitalo K, Hemmings BA, Yang Z*, He Y*. Akt / Protein Kinase B is required for lymphatic network formation, remodeling and valve development. Am J Pathol 177: 2124-2133 (2010).

21、Holopainen T^#, Huang H^#, Chen C^#, Kim KE, Zhang L, Zhou F, Han W, Li C, Yu J, Wu J, Koh GY, Alitalo K*, He Y*. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Res 69:4656-64 (2009).

22、Tammela T^#, He Y^#, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, Ylä-Herttuala S, AlitaloK. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circ Res100:1468-75 (2007).

23、Wirzenius M, Tammela M, Uutela M, He Y, Odorisio1 T, Zambruno1 G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M and Alitalo K. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 204:1431-40 (2007).医学1区

24、He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. VEGFR-3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65:4739-46(2005).

25、Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65:6901-9 (2005).

26、Bhardwaj S, Roy H, Karpanen T, He Y, Jauhiainen S, Hedman M, Alitalo K, Yla-Herttuala S. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Ther 12:388-94 (2005).

27、He Y^#, Rajantie I^#, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64:3737-40 (2004).

28、He Y, Karpanen T and Alitalo K. Role of lymphangiogenic factors in lymphatic tumor metastasis. Biochim Biophys Acta （BBA Review Cancer） 1654:3-12(2004).

29、Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure and blood vessel maturation during angiogenesis. Blood 104:3198-204 (2004).

30、He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:785-7 (2002).

31、Smith SK, He Y, Clark DE, Charnock-Jones DS. Angiogenic growth factor expression in placenta. Semin Perinatol 24, 82-86 (2000).

32、He Y*, Smith SK, Day KA, Clark D, Licence DR, Charnock-Jones DS*. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.  Mol Endocrinol 13:537-545 (1999).

33、Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, and Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the placenta and released into the maternal circulation.  Biol Reprod 59:1540-1548 (1998).

Contact:

Phone: +86 512 65880899-3621, 13626199438

Email:heyulong@suda.edu.cn；yhe20005@gmail.com

Fax: +86 512 65880929

Office: Building 703, room 3621, Cyrus Tang Hematology Center, Soochow University